Clinical Trial Update: A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of VB-111 with paclitaxel for platinum-resistant ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Platinum-resistant Ovarian Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• VB-111

Snippet

Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics | Conditions: Platinum Resistant Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED